Surmodics, Inc. (SRDX) News
Filter SRDX News Items
SRDX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SRDX News Highlights
- SRDX's 30 day story count now stands at 8.
- Over the past 25 days, the trend for SRDX's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- DRUG and PATH are the most mentioned tickers in articles about SRDX.
Latest SRDX News From Around the Web
Below are the latest news stories about SURMODICS INC that investors may wish to consider to help them evaluate SRDX as an investment opportunity.
SurModics (SRDX) Surges 6.1%: Is This an Indication of Further Gains?SurModics (SRDX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
Surmodics (SRDX) Stock Skids 32% on Negative Regulatory UpdateSurmodics' (SRDX) SurVeil drug-coated balloon candidate receives additional data requests from the FDA. |
Surmodics Provides Regulatory Update Related to its FDA Premarket Approval Application for the SurVeil Drug-Coated BalloonSurmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced it has received a letter from the U.S. Food and Drug Administration (FDA; the Agency) related to its premarket approval (PMA) application for the SurVeil drug-coated balloon (DCB). In the letter, the FDA indicated that the application is not currently |
Surmodics Stock Slides Following Regulatory Setback For Its SurVeil Drug-Coated BalloonSurmodics Inc (NASDAQ: SRDX) has received a letter from the FDA related to its premarket approval (PMA) application for the SurVeil drug-coated balloon (DCB). In the letter, the FDA indicated that the application is not currently approvable while providing specific guidance on a path forward. The letter stated that certain information within two general categories—biocompatibility and labeling—must be added by an amendment to the company's PMA application to place it in approvable form. Although |
Differentiated Capabilities of Surmodics’ Crystalline Drug Release Platform for Sirolimus-Coated Balloons Presented at ISET ConferenceEDEN PRAIRIE, Minn., January 19, 2023--The Sundance™ SCB delivers drug to target tissue via a coating of stable crystalline sirolimus with a proprietary excipient on the balloon surface. |
Surmodics Provides Regulatory Update Related to its FDA Premarket Approval Application for the SurVeil™ Drug-Coated BalloonEDEN PRAIRIE, Minn., January 19, 2023--Surmodics received a letter from the FDA that indicated that the PMA application for the SurVeil™ drug-coated balloon is not currently approvable. |
Surmodics Announces SWING Trial 12-Month Data to be Presented at ISET Conference on January 18EDEN PRAIRIE, Minn., January 16, 2023--Professor Varcoe will present data from the SWING Trial, a FIH study of the safety and performance of the Sundance™ Sirolimus Drug-Coated Balloon. |
3 Reasons to Retain Surmodics (SRDX) Stock in Your PortfolioInvestors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business. |
Wall Street Analysts Are Bullish on Top Healthcare PicksThere's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on SurModics (SRDX – Research Report) and Axsome Therapeutics (AXSM – Research Report) with bullish sentiments. SurModics (SRDX) In a report released today, Michael Petusky from Barrington maintained a Buy rating on SurModics, with a price target of $70.00. The company's shares closed last Thursday at $32.86. According to TipRanks. |
Surmodics Announces 12-Month Data from the SWING Trial Presented at VEITHsymposiumEDEN PRAIRIE, Minn., November 17, 2022--Surmodics Announces 12-Month Data from the SWING Trial Presented at VEITHsymposium |